Skip to main content

The World Since 1945



Random reading....

In the February issue of HARPER'S, Rebecca Solnit works to relate the Second World War to ... every environmental disaster since.

The following may be the money quote.

"In crucial, material ways, the technological modernization of World War II never ended. Pesticides, nuclear engineering, and plastics -- all developed during the militarization of industrial production -- are now part of a war by other means. All three industries sought profitable postwar applications and found them in agriculture, in energy production, and in the creation of untold disposable plastic items, the ubiquity of which was aided by he rise of advertising and marketing."

The reference to pesticides there brought me up short. Are pesticides the consequence of that war in the same  sense as nuclear engineering? Sulfur was used as a pesticide by the Chinese back around 1,000 BC. My understanding is that the modern and highly marketable nature of pesticides dates back to the days of Walter Reed, in the 1890s and early 1900s. It was Reed who determined that yellow fever is caused by mosquitoes, creating an obvious demand for ever-better ways to kill the carriers of that and (as it turns out) other diseases.

Solnit says nothing more on pesticides in her essay, and little on nukes or plastic either, but soon focuses on the issue of moving carbon from the ground into the air. A matter where her WW II connection is even less obvious.

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…